Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
Publication date
2015-06-19
Authors
Ustianowski, Andrew
Arends, Joop E.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.
Keywords
Efficacy, HIV, Tenofovir, Toxicity, Infectious Diseases, Microbiology (medical)
Citation
Ustianowski, A & Arends, J E 2015, 'Tenofovir : What We Have Learnt After 7.5 Million Person-Years of Use', Infectious Diseases and Therapy, vol. 4, no. 2, pp. 145-157. https://doi.org/10.1007/s40121-015-0070-1